Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

The high incidence of resistance to Tyrosine Kinase Inhibitors (TKIs) targeted against EGFR and downstream pathways has increased the necessity to identify agents that may be combined with these therapies to provide a sustained response for breast cancer patients. Here, we investigate the therapeuti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Cancer
Hauptverfasser: Suárez-Arroyo, Ivette J., Rios-Fuller, Tiffany J., Feliz-Mosquea, Yismeilin R., Lacourt-Ventura, Mercedes, Leal-Alviarez, Daniel J., Maldonado-Martinez, Gerónimo, Cubano, Luis A., Martínez-Montemayor, Michelle M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Ivyspring International Publisher 2016
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780125/
https://ncbi.nlm.nih.gov/pubmed/26958085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.13599
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge